GlassScriptPhysician profile
Larry Doehring
NPI 1326019001
$263.23
in general payments reported to CMS, 2019-2025
12 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $217 · 2020: $25.09 · 2021: $20.87.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $65.67 | 2019-2020 | |
| Novo Nordisk INC | $38.73 | 2019-2021 | |
| Astrazeneca Pharmaceuticals LP | $36.63 | 2019-2020 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $35.90 | 2019 | |
| Glaxosmithkline, LLC. | $16.86 | 2019 | |
| Amgen INC. | $15.68 | 2019 | |
| Astellas Pharma US INC | $14.56 | 2019 | |
| Shire North American Group INC | $13.97 | 2019 | |
| Teva Pharmaceuticals USA, INC. | $13.02 | 2019 | |
| Amarin Pharma, INC. | $12.21 | 2019 |
2 companies reported research payments only; those appear in the research section below.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Larry Doehring listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.